Success Metrics

Clinical Success Rate
82.1%

Based on 23 completed trials

Completion Rate
82%(23/28)
Active Trials
5(9%)
Results Posted
17%(4 trials)
Terminated
5(9%)

Phase Distribution

Ph phase_2
18
32%
Ph phase_1
7
12%
Ph not_applicable
9
16%
Ph phase_3
7
12%
Ph phase_4
14
25%

Phase Distribution

7

Early Stage

18

Mid Stage

21

Late Stage

Phase Distribution55 total trials
Phase 1Safety & dosage
7(12.7%)
Phase 2Efficacy & side effects
18(32.7%)
Phase 3Large-scale testing
7(12.7%)
Phase 4Post-market surveillance
14(25.5%)
N/ANon-phased studies
9(16.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

74.2%

23 of 31 finished

Non-Completion Rate

25.8%

8 ended early

Currently Active

5

trials recruiting

Total Trials

57

all time

Status Distribution
Active(6)
Completed(23)
Terminated(8)
Other(20)

Detailed Status

Completed23
unknown20
Terminated5
Recruiting4
Withdrawn3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
57
Active
5
Success Rate
82.1%
Most Advanced
Phase 4

Trials by Phase

Phase 17 (12.7%)
Phase 218 (32.7%)
Phase 37 (12.7%)
Phase 414 (25.5%)
N/A9 (16.4%)

Trials by Status

completed2340%
not_yet_recruiting12%
active_not_recruiting12%
recruiting47%
terminated59%
unknown2035%
withdrawn35%

Recent Activity

Clinical Trials (57)

Showing 20 of 57 trialsScroll for more
NCT07525401Not Applicable

Comparative Evaluation of Oral Ursodeoxycholic Acid in Reducing Bilirubin Levels Among Patients With Acute Viral Hepatitis

Not Yet Recruiting
NCT06517862Phase 4

Efficacy & Safety of Oral Adjuvants to Phototherapy in Neonatal Hyperbilirubinemia

Recruiting
NCT06091787Not Applicable

Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration on Right Lobe Donor Hepatectomy

Completed
NCT06610760Phase 4

Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia

Recruiting
NCT04407650Phase 4

Ursodeoxycholic Acid vs Metformin in Gestational Diabetes Mellitus

Active Not Recruiting
NCT04650243Phase 4

Clinical Research of Tapering UDCA in PBC Patients With a Complete Response

Recruiting
NCT03188146

Performance of Scoring Systems in Chinese Patients With Primary Biliary Cholangitis (PBC) on Ursodeoxycholic Acid

Completed
NCT04924868Phase 3

Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis

Recruiting
NCT05659654Phase 1

The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19)

Completed
NCT05526807Not Applicable

Ursodeoxycholic Acid in C. Difficile Infection

Terminated
NCT05902468Phase 2

Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus

Unknown
NCT03602976Phase 2

Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis

Terminated
NCT05812612

UDCA in the Treatment of COVID-19 Infection and Its Clinical Prognosis in Patients With Autoimmune Liver Disease

Unknown
NCT05690646Phase 4

Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery

Unknown
NCT04542473Phase 2

Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished Children

Unknown
NCT05467553Phase 2

A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection

Unknown
NCT04910178Phase 4

Follow-up of NAFLD Patients With MRI-PDFF

Completed
NCT04810156Phase 2

Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis

Unknown
NCT02967250Phase 1

Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment

Completed
NCT02936596Not Applicable

Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome

Unknown

Drug Details

Intervention Type
DRUG
Total Trials
57